Plasmodium Vivax Infection
9
3
3
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
22%
2 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
Clinical Study to Assess Minimum Mosquito Bites for P. Vivax Infection in Thai Adults
A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 )
Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia
A Controlled Human Vivax Malaria Infection Study Through Inoculation of Infected Erythrocytes
Vivax Malaria Human Infection Studies in Thailand
Comparative Study of Thrombocytopenia in Plasmodium Vivax and Falciparum Malaria
Efficacy and Safety of Dihydroartemisinin-piperaquine (DHP) for the Treatment of Uncomplicated Malaria
Ethiopia Antimalarial in Vivo Efficacy Study 2012
Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity